Notable Analyst Rating Changes 12/4: (TEVA) (HBI) (HPP) Upgraded; (M)( GPRO) (KSU) Downgraded
Tweet Send to a Friend
UPGRADES
Guggenheim upgrades Teva Pharma (NYSE: TEVA) from Neutral to Buy with a price target of $80. Click Here ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Guggenheim upgrades Teva Pharma (NYSE: TEVA) from Neutral to Buy with a price target of $80. Click Here ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
